| Oct 15 |
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
|
| Sep 27 |
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
|
| Aug 15 |
Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
|
| Aug 14 |
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 14 |
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 15 |
Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?
|
| May 21 |
Lyra to cut 75% of workforce in portfolio shakeup
|
| May 21 |
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
|
| May 7 |
Jefferies cuts Lyra to hold in wake of failed Phase 3 study
|
| May 7 |
Target upgraded, CVS downgraded: Wall Street's top analyst calls
|
